10X GENOMICS INC-CLASS A (TXG) Fundamental Analysis & Valuation

NASDAQ:TXG • US88025U1097

Current stock price

25.23 USD
-0.12 (-0.47%)
Last:

This TXG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. TXG Profitability Analysis

1.1 Basic Checks

  • TXG had negative earnings in the past year.
  • In the past year TXG had a positive cash flow from operations.
  • TXG had negative earnings in each of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: TXG reported negative operating cash flow in multiple years.
TXG Yearly Net Income VS EBIT VS OCF VS FCFTXG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -4.18%, TXG is in line with its industry, outperforming 56.14% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -5.47%, TXG is in line with its industry, outperforming 57.89% of the companies in the same industry.
Industry RankSector Rank
ROA -4.18%
ROE -5.47%
ROIC N/A
ROA(3y)-16.83%
ROA(5y)-14.47%
ROE(3y)-21.87%
ROE(5y)-18.67%
ROIC(3y)N/A
ROIC(5y)N/A
TXG Yearly ROA, ROE, ROICTXG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

  • TXG's Gross Margin of 69.13% is amongst the best of the industry. TXG outperforms 91.23% of its industry peers.
  • TXG's Gross Margin has declined in the last couple of years.
  • TXG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.4%
GM growth 5Y-2.99%
TXG Yearly Profit, Operating, Gross MarginsTXG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. TXG Health Analysis

2.1 Basic Checks

  • TXG does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TXG has more shares outstanding than it did 1 year ago.
  • TXG has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for TXG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TXG Yearly Shares OutstandingTXG Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
TXG Yearly Total Debt VS Total AssetsTXG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 6.81 indicates that TXG is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.81, TXG belongs to the top of the industry, outperforming 87.72% of the companies in the same industry.
  • TXG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 6.81
ROIC/WACCN/A
WACC10.82%
TXG Yearly LT Debt VS Equity VS FCFTXG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 4.46 indicates that TXG has no problem at all paying its short term obligations.
  • TXG has a better Current ratio (4.46) than 71.93% of its industry peers.
  • TXG has a Quick Ratio of 4.09. This indicates that TXG is financially healthy and has no problem in meeting its short term obligations.
  • TXG has a Quick ratio of 4.09. This is in the better half of the industry: TXG outperforms 75.44% of its industry peers.
Industry RankSector Rank
Current Ratio 4.46
Quick Ratio 4.09
TXG Yearly Current Assets VS Current LiabilitesTXG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. TXG Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 71.71% over the past year.
  • TXG shows a small growth in Revenue. In the last year, the Revenue has grown by 5.25%.
  • TXG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.56% yearly.
EPS 1Y (TTM)71.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.5%
Revenue 1Y (TTM)5.25%
Revenue growth 3Y7.57%
Revenue growth 5Y16.56%
Sales Q2Q%0.61%

3.2 Future

  • Based on estimates for the next years, TXG will show a very strong growth in Earnings Per Share. The EPS will grow by 26.18% on average per year.
  • The Revenue is expected to grow by 5.75% on average over the next years.
EPS Next Y-127.32%
EPS Next 2Y-32.67%
EPS Next 3Y-4.68%
EPS Next 5Y26.18%
Revenue Next Year-3.5%
Revenue Next 2Y1.77%
Revenue Next 3Y3.9%
Revenue Next 5Y5.75%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TXG Yearly Revenue VS EstimatesTXG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TXG Yearly EPS VS EstimatesTXG Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -1 -2 -3 -4 -5

More info and screens

Find the best growth stocksShow best growing peers

1

4. TXG Valuation Analysis

4.1 Price/Earnings Ratio

  • TXG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year TXG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TXG Price Earnings VS Forward Price EarningsTXG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, TXG is valued a bit cheaper than 73.68% of the companies in the same industry.
Industry RankSector Rank
P/FCF 24.77
EV/EBITDA N/A
TXG Per share dataTXG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • A cheap valuation may be justified as TXG's earnings are expected to decrease with -4.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-32.67%
EPS Next 3Y-4.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TXG Dividend Analysis

5.1 Amount

  • No dividends for TXG!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TXG Fundamentals: All Metrics, Ratios and Statistics

10X GENOMICS INC-CLASS A

NASDAQ:TXG (4/16/2026, 3:58:56 PM)

25.23

-0.12 (-0.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12
Earnings (Next)05-06
Inst Owners107.08%
Inst Owner Change0.05%
Ins Owners1.84%
Ins Owner Change9.29%
Market Cap3.22B
Revenue(TTM)642.82M
Net Income(TTM)-43.54M
Analysts72.73
Price Target20.69 (-17.99%)
Short Float %13.88%
Short Ratio6.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.91%
Min EPS beat(2)24.4%
Max EPS beat(2)39.41%
EPS beat(4)4
Avg EPS beat(4)65.69%
Min EPS beat(4)24.36%
Max EPS beat(4)174.61%
EPS beat(8)7
Avg EPS beat(8)34.54%
EPS beat(12)7
Avg EPS beat(12)12.19%
EPS beat(16)9
Avg EPS beat(16)9.62%
Revenue beat(2)2
Avg Revenue beat(2)3.37%
Min Revenue beat(2)3.21%
Max Revenue beat(2)3.54%
Revenue beat(4)4
Avg Revenue beat(4)11.32%
Min Revenue beat(4)3.21%
Max Revenue beat(4)22.78%
Revenue beat(8)6
Avg Revenue beat(8)5.2%
Revenue beat(12)9
Avg Revenue beat(12)4.07%
Revenue beat(16)12
Avg Revenue beat(16)3.14%
PT rev (1m)1.79%
PT rev (3m)17.94%
EPS NQ rev (1m)-0.54%
EPS NQ rev (3m)-3.72%
EPS NY rev (1m)-0.31%
EPS NY rev (3m)-1.31%
Revenue NQ rev (1m)0.2%
Revenue NQ rev (3m)2.81%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)0.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.01
P/FCF 24.77
P/OCF 23.69
P/B 4.05
P/tB 4.42
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.98
Fwd EYN/A
FCF(TTM)1.02
FCFY4.04%
OCF(TTM)1.06
OCFY4.22%
SpS5.03
BVpS6.23
TBVpS5.71
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -4.18%
ROE -5.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.13%
FCFM 20.24%
ROA(3y)-16.83%
ROA(5y)-14.47%
ROE(3y)-21.87%
ROE(5y)-18.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.4%
GM growth 5Y-2.99%
F-Score5
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 16.4%
Cap/Sales 0.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.46
Quick Ratio 4.09
Altman-Z 6.81
F-Score5
WACC10.82%
ROIC/WACCN/A
Cap/Depr(3y)64.39%
Cap/Depr(5y)238.34%
Cap/Sales(3y)3.71%
Cap/Sales(5y)11.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.5%
EPS Next Y-127.32%
EPS Next 2Y-32.67%
EPS Next 3Y-4.68%
EPS Next 5Y26.18%
Revenue 1Y (TTM)5.25%
Revenue growth 3Y7.57%
Revenue growth 5Y16.56%
Sales Q2Q%0.61%
Revenue Next Year-3.5%
Revenue Next 2Y1.77%
Revenue Next 3Y3.9%
Revenue Next 5Y5.75%
EBIT growth 1Y48.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-235.7%
EBIT Next 3Y-3.59%
EBIT Next 5Y6.3%
FCF growth 1Y2033.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1941.57%
OCF growth 3YN/A
OCF growth 5YN/A

10X GENOMICS INC-CLASS A / TXG Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for 10X GENOMICS INC-CLASS A?

ChartMill assigns a fundamental rating of 4 / 10 to TXG.


What is the valuation status of 10X GENOMICS INC-CLASS A (TXG) stock?

ChartMill assigns a valuation rating of 1 / 10 to 10X GENOMICS INC-CLASS A (TXG). This can be considered as Overvalued.


What is the profitability of TXG stock?

10X GENOMICS INC-CLASS A (TXG) has a profitability rating of 2 / 10.


What is the earnings growth outlook for 10X GENOMICS INC-CLASS A?

The Earnings per Share (EPS) of 10X GENOMICS INC-CLASS A (TXG) is expected to decline by -127.32% in the next year.